A practical reference on GW501516: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-30. Anything still debated is marked as such rather than presented as settled.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
== Mechanism of action == DBNPA is a moderate electrophile. It acts as a broad-spectrum, non-oxidizing biocide by very quickly disrupting important cellular processes in microorganisms like bacteria, fungi and algae, ultimately causing cell death. Its primary mechanism involves penetrating the cell membrane and targeting nucleophilic sites, and relies on bromine interacting with sulfur containing groups on proteins critical for cellular metabolism. Once inside the cell, DBNPA reacts with these sulfur-containing groups, forming covalent bonds that inactivate enzymes involved in redox equations. This disruption is irreversible and stops energy production, leading to cell death within 5–10 minutes of exposure. To summarize, DBNPA stops biofouling in water systems, which is the undesirable accumulation of microorganisms, very quickly, by permanently attacking microbiological cell walls. The non-oxidative mechanism distinguishes DBNPA from other oxidizing agents like bleach; instead of oxidizing cellular components broadly, DBNPA selectively targets functional protein groups, making it effective against pathogens like gram-negative bacteria and fungi. For example, in cooling water systems, DBNPA has been shown to reduce gram-negative bacteria Legionella pneumophila counts by 99.9% within 10 minutes, at low concentrations of 5 mg/L.
=== Israeli−Palestinian conflict === Hitchens described Zionism as "an ethno-nationalist quasi-religious ideology" but argued that Zionism "nonetheless has founded a sort of democratic state which isn't any worse in its practice than many others with equally dubious origins." He stated that Israeli settlements on Palestinian territory to achieve security for Israel are "doomed to fail in the worst possible way", and the cessation of this "appallingly racist and messianic delusion" would "confront the internal clerical and chauvinist forces which want to instate a theocracy for Jews". Hitchens contended that the "solution of withdrawal would not satisfy the jihadists" and wondered "What did they imagine would be the response of the followers of the Prophet [Muhammad]?" Hitchens bemoaned the transference of Arab secularism into religious terrorism as a means of democratisation: "the most depressing and wretched spectacle of the past decade, for all those who care about democracy and secularism, has been the degeneration of Palestinian Arab nationalism into the theocratic and thanatocratic hell of Hamas and Islamic Jihad". On 14 November 2004, Hitchens noted:
This was elegantly restated in 1963 in a plaque unveiled at Johns Hopkins to commemorate the major contribution (of McLean) to the discovery of heparin in 1916 in collaboration with Professor William Henry Howell. In the 1930s, several researchers were investigating heparin. Erik Jorpes at Karolinska Institutet published his research on the structure of heparin in 1935, which made it possible for the Swedish company Vitrum AB to launch the first heparin product for intravenous use in 1936. Between 1933 and 1936, Connaught Medical Research Laboratories, then a part of the University of Toronto, perfected a technique for producing safe, nontoxic heparin that could be administered to patients, in a saline solution. The first human trials of heparin began in May 1935, and, by 1937, it was clear that Connaught's heparin was safe, easily available, and effective as a blood anticoagulant. Before 1933, heparin was available in small amounts, was extremely expensive and toxic, and, as a consequence, of no medical value. Heparin production experienced a break in the 1990s. Until then, heparin was mainly obtained from cattle tissue, which was a by-product of the meat industry, especially in North America. With the rapid spread of BSE, more and more manufacturers abandoned this source of supply. As a result, global heparin production became increasingly concentrated in China, where the substance was now procured from the expanding industry of breeding and slaughtering hogs.
N,N′-Diisopropylcarbodiimide is a carbodiimide used in peptide synthesis. As a liquid, it is easier to handle than the commonly used N,N′-dicyclohexylcarbodiimide, a waxy solid. In addition, N,N′-diisopropylurea, its byproduct in many chemical reactions, is soluble in most organic solvents, a property that facilitates work-up.
Sources: en.wikipedia.org
Israelite presence in Canaan was also established before Joshua's conquests according to a few biblical traditions. The history of the Israelite people can be divided into these categories, according to the Hebrew Bible:
Dekaranger, Ban acquires a variant of the SP License called the Fire Squad License (ファイヤースクワッドライセンス, Faiyā Sukuwaddo Raisensu), which allows him to transform Murphy K-9 into his armor to assume Battlizer Mode (バトライザーモード, Batoriza Mōdo) where he gains a rocket booster pack and a pair of siren lasers. In this form, he wields a sword/rifle hybrid, which allows him to perform the Battlize Fire Drive (バトライズファイヤードライブ, Batoraizu Faiyā Doraibu) finisher. As of the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, Ban has acquired a red-colored S.W.A.T. Mode vest to signify his membership in the Fire Squad. During the events of the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster, he acquires a variant of the SP License called the SP1 License (SP1ライセンス, Esu Pī Wan Raisensu), which allows him to transform into the armored Premiere Deka Red (プレミアデカレッド, Puremia Deka Reddo). While transformed, he wields the D-Sword Vega, which allows him to perform the Boost Slash (ブーストスラッシュ, Būsuto Surasshu) finisher. Ban is portrayed by Ryuji Sainei (載寧 龍二, Sainei Ryūji).
During this period, Humboldt investigated the fate of the Guanches, the indigenous people of the Canaries, concluding that they had been destroyed by European conquest and slavery, with survivors assimilated into the Spanish population. The Pizarro crossed the Tropic of Cancer on June 27, sailing through the Atlantic and carefully avoiding the area labeled “Bank of Maal-strom,” whose dangers Humboldt doubted existed in the calm tropics. The ship passed west of the Cape Verde Islands, once claimed for Portugal by Alvise da Mosto, and entered the Sargasso Sea, a vast region of floating seaweed previously described by Columbus. Here, the crew encountered a partially submerged, abandoned ship covered in seaweed, which Humboldt surmised had drifted from the rough North Atlantic rather than sinking locally. Throughout the voyage, Humboldt and Bonpland conducted systematic scientific observations, measuring a wide array of atmospheric and oceanic variables and recording them meticulously. The two naturalists spent their evenings observing unfamiliar southern constellations, including the Southern Cross, which stirred Humboldt’s sense of distance from Europe. The ship enjoyed a relatively smooth journey across the Atlantic, following established routes aided by predictable trade winds. The calm seas known as el Golfo de las Damas made for easy sailing, and the crew rarely needed to adjust the sails. Approaching the West Indies, the weather changed, with frequent tropical squalls and the distinctive "dark winds," phenomena new to Humboldt but familiar in the region.
Sources: en.wikipedia.org
Activated protein C–protein C inhibitor (APC-PCI) is a complex of activated protein C (APC) and protein C inhibitor (PCI). It has been measured in coagulation testing to evaluate coagulation, thrombosis, and other cardiovascular complications. It is a marker of thrombin generation and indicates hypercoagulability or presence of thrombosis. Activated Protein C is a vitamin K-dependent serine protease that cleaves and inactivates Factor Va and Factor VIIIa, thus acting as an anticoagulant. Protein C Inhibitor is a 54-kilodalton glycoprotein of the serpin superfamily. Like other serpins, upon cleavage by PC, PCI undergoes a dramatic conformational rearrangement resulting in a stable covalent bond between the two proteins. The resulting PC-PCI protein dimer lacks enzyme activity and is permanently inactivated, an example of suicide inhibition. Formation of this complex is one of the major means of regulation of protein C activity, so that pro-coagulation and anticoagulant activities are kept in balance.
== Nuclear properties == Technetium-99m is a metastable nuclear isomer, as indicated by the "m" after its mass number 99. This means it is a nuclide in an excited (metastable) state that lasts much longer than is typical. The nucleus will eventually relax (i.e., de-excite) to its ground state through the emission of gamma rays or internal conversion electrons. These decays do not change the number of protons or neutrons, but only give them a lower-energy 'arrangement', which here is the ground state. The excitation energy above the ground state is 142.7 keV, but 99% of the time, it relaxes first to a slightly lower state (140.5 keV) by internal conversion (and the rate of this transition determines the uncertainty in half-life), which decays at once. In total, 99mTc decays about 89% by gamma emission (99mTc → 99Tc + γ) and almost all of the time, this results in a 140.5 keV gamma ray and only rarely in a 142.7 keV (1 in 4,000) as the latter decay, too, is very largely converted. The remaining 11% of decays are completed entirely by conversion and not of diagnostic utility, though still contributing to internal radiation dose. These gammas are the radiations that are picked up by a gamma camera when 99mTc is used as a radioactive tracer for medical imaging. Pure gamma emission is the desirable decay mode for medical imaging because other particles deposit more energy in the patient body (radiation dose) relatively to that in the camera. Metastable isomeric transition is the only nuclear decay mode that approaches pure gamma emission.
== Combination with other antidiabetic drugs == A combination therapy of insulin and other antidiabetic drugs appears to be most beneficial in people who are diabetic, who still have residual insulin secretory capacity. A combination of insulin therapy and sulfonylurea is more effective than insulin alone in treating people with type 2 diabetes after secondary failure to oral drugs, leading to better glucose profiles or decreased insulin needs.
In March 2009, Komsomolskaya Pravda reported that on the morning of 8 August 2008, at around 6:00 AM tank shell hit the observer post and wounded lieutenant Oleg Galavanov. Galavanov had returned from Russia to Tskhinvali in 2007 and worked in the Ministry of Defense and Emergency Situations of South Ossetia. He served as artillery spotter. In August 2009, South Ossetian news agency RES reported that 32-year old Oleg Galavanov had been promoted to the rank of lieutenant in 2007. In October 2008, Konstantin Timerman, the commander of the Russian peacekeeping battalion, said in an interview with Izvestia that on the morning of 8 August the Russians opened fire in response only after the Georgians had opened fire on the observer post in the southern part of Tskhinvali. If we take into consideration that Golovanov is listed as an employee of the South Ossetian Defense Ministry, it turns out that the Georgian fire against the Russian peacekeeping base was provoked by the Ossetian fire from the roof. In 2009, the Russian authorities told the Tagliavini commission that the Russian peacekeepers suffered the first casualties at 6:35 am on 8 August, when the Georgian tank was firing on the observer post on the roof of the peacekeepers' base. As a result one soldier of the battalion died, another one was wounded and the part of the building was destroyed. By noon two peacekeepers had died and five were wounded. Georgia said that it only targeted Russian peacekeepers in self-defence, after coming under fire from them.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.